PAVmed to Hold Business Update Conference Call on May 17, 2021
May 03 2021 - 9:30AM
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”
or “PAVmed”), a highly differentiated, multi-product,
commercial-stage medical device company, today announced that the
Company will host a business update conference call on Monday, May
17, 2021 at 4:30 PM EDT. During the call, Lishan Aklog, M.D.,
Chairman and Chief Executive Officer of the Company, will provide a
business update including an overview of the Company’s near-term
milestones and growth strategy. In addition, Dennis McGrath, the
Company’s President and Chief Financial Officer, will discuss first
quarter 2021 financial results.
To access the conference call, U.S.-based
listeners should dial (877) 407-3982 and international listeners
should dial (201) 493-6780. All listeners should provide the
operator with the conference call name “PAVmed, Inc. Business
Update Conference Call” to join. Individuals interested in
listening to the live conference call via webcast may do so by
visiting the investor relations section of the Company’s website at
www.pavmed.com.
Following the conclusion of the conference call,
a replay will be available for one week and can be accessed by
dialing (844) 512-2921 from within the U.S. or (412) 317-6671 from
outside the U.S. To access the replay, all listeners should provide
the following pin number: 13719121. The webcast will be available
for replay on the investor relations section of the Company’s
website at www.pavmed.com.
About PAVmed and
LucidPAVmed Inc. is a highly differentiated,
multi-product, commercial-stage medical technology company with a
diversified product pipeline addressing unmet clinical needs
encompassing a broad spectrum of clinical areas with attractive
regulatory pathways and market opportunities. Its major subsidiary,
Lucid Diagnostics Inc., markets the first and only commercial tools
for widespread early detection of esophageal precancer and cancer –
the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device. Its GI Health
division also includes the complementary EsoCure™ Esophageal
Ablation Device with Caldus™ Technology. Its Minimally
Invasive Interventions markets its CarpX® Minimally Invasive
Device for Carpal Tunnel Syndrome. Other divisions include Infusion
Therapy (PortIO™ Implantable Intraosseus Vascular Access
Device and NextFlo™ Intravenous Infusion Set), and Emerging
Innovations (non-invasive laser-based glucose monitoring, pediatric
ear tubes, and mechanical circulatory support). For more
information, please visit www.pavmed.com, follow us
on Twitter, connect with us on LinkedIn, and watch our
videos on YouTube. For more information on our majority owned
subsidiary, Lucid Diagnostics Inc., please
visit www.luciddx.com, follow Lucid on Twitter, and
connect with Lucid on LinkedIn. For detailed information on
EsoGuard, please visit www.EsoGuard.com and follow us
on Twitter, Facebook and Instagram.
Forward-Looking StatementsThis
press release includes forward-looking statements that involve
risks and uncertainties. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements,
based upon the current beliefs and expectations of PAVmed’s
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of PAVmed’s common
stock, Series W Warrants and Series Z Warrants; general economic
and market conditions; the uncertainties inherent in research and
development, including the cost and time required advance PAVmed’s
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from PAVmed’s
preclinical studies; whether and when PAVmed’s products are cleared
by regulatory authorities; market acceptance of PAVmed’s products
once cleared and commercialized; our ability to raise additional
funding and other competitive developments. PAVmed has not yet
received clearance from the FDA or other regulatory body to market
many of its products. The Company has been monitoring the COVID-19
pandemic and its impact on our business. The Company expects the
significance of the COVID-19 pandemic, including the extent of its
effect on the Company’s financial and operational results, to be
dictated by, among other things, the success of efforts to contain
it and the impact of actions taken in response. New risks and
uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s control.
For a further list and description of these and other important
risks and uncertainties that may affect PAVmed’s future operations,
see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after
its most recent Annual Report. PAVmed disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
Contacts:Investors Mike Havrilla Director of
Investor Relations (814) 241-4138 JMH@PAVmed.com
Media Shaun O’Neil Chief Commercial Officer (518) 812-3087
SMO@PAVmed.com
Jim Heins / Katie Gallagher LaVoieHealthScience (646) 491-7042 /
(617) 792-3937 PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Jul 2023 to Jul 2024